Company continues to advance QRX003 in late-stage clinical trials in Netherton Syndrome patients Regulatory milestone ...

QRX003 is being well tolerated by the patient and no adverse events have been reported. As a result of these positive initial ...

Announced Positive Clinical Data for Adult and Pediatric Netherton Patients ASHBURN, Va., May 13, 2025 (GLOBE NEWSWIRE) -- ...

Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling ...

Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa, Microcystic Lymphatic Malformations, Venous Malformations, Angiofibroma and others. For more information, visit: The Company cautions ...

Zeit Aktuelle Nachrichten 14:06 Quoin Pharmaceuticals regains Nasdaq compliance 13:46 Quoin Pharmaceuticals erfüllt wieder NASDAQ-Mindestangebotspreisanforderung 13: ...

Patient with palmoplantar keratoderma areata6 It will be quite some time before all rare disease patients can truly say they feel their opinions are taken into account. However the stories of ...

ASHBURN, Va., April 30, 2025 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a late clinical stage, specialty ...

A focused evaluation of scalp hair should be part of every newborn physical assessment. Although typically completed in the delivery room, it may be useful to re-evaluate the infant after the ...